U.S. patent application number 14/509437 was filed with the patent office on 2015-01-29 for antibodies to the pcrv antigen of pseudomonas aeruginosa. The applicant listed for this patent is KaloBios Pharmaceuticals, Inc.. Invention is credited to Mark Baer, Christopher R. Bebbington, Kenneth Luehrsen, Geoffrey T. Yarranton.
Application Number | 20150030614 14/509437 |
Document ID | / |
Family ID | 40527381 |
Filed Date | 2015-01-29 |
United States Patent Application | 20150030614 |
Kind Code | A1 |
Bebbington; Christopher R. ; et al. | January 29, 2015 |
The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.
Inventors: | Bebbington; Christopher R.; (San Mateo, CA) ; Luehrsen; Kenneth; (Half Moon Bay, CA) ; Yarranton; Geoffrey T.; (Burlingame, CA) ; Baer; Mark; (San Francisco, CA) | ||||||||||
Applicant: |
|
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Family ID: | 40527381 | ||||||||||
Appl. No.: | 14/509437 | ||||||||||
Filed: | October 8, 2014 |
Application Number | Filing Date | Patent Number | ||
---|---|---|---|---|
13271146 | Oct 11, 2011 | 8877191 | ||
14509437 | ||||
12325806 | Dec 1, 2008 | 8044181 | ||
13271146 | ||||
60991679 | Nov 30, 2007 | |||
Current U.S. Class: | 424/170.1 ; 530/389.5; 530/391.1 |
Current CPC Class: | C07K 2317/56 20130101; C07K 2317/567 20130101; A61P 31/04 20180101; C07K 2317/21 20130101; A61K 2039/505 20130101; C07K 2317/55 20130101; A61K 39/40 20130101; C07K 2317/92 20130101; A61K 47/60 20170801; C07K 2317/24 20130101; C07K 2317/76 20130101; A61P 31/10 20180101; C07K 2317/565 20130101; C07K 16/1214 20130101 |
Class at Publication: | 424/170.1 ; 530/389.5; 530/391.1 |
International Class: | C07K 16/12 20060101 C07K016/12; A61K 39/40 20060101 A61K039/40; A61K 47/48 20060101 A61K047/48 |
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 119 <210> SEQ ID NO 1 <211> LENGTH: 124
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh (VH1) V-region <400> SEQUENCE: 1 Glu
Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10
15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His
20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45 Gly Trp Ile Ser Pro Tyr Ser Gly Asn Pro Asn Tyr
Ala Gln Ser Leu 50 55 60 Gln Gly Arg Val Ser Leu Thr Thr Asp Arg
Ser Thr Arg Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Lys Ser
Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Phe Asp 100 105 110 Ile Trp Gly Gln
Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 2
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody VkappaI V-region
<400> SEQUENCE: 2 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Arg Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Gly Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu
Asp Val Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85 90
95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210>
SEQ ID NO 3 <211> LENGTH: 124 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 3 Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Thr Ala 20 25 30 Gly Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 4 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaI V-region <400> SEQUENCE: 4 Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Trp 20
25 30 Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Asn Leu Leu
Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln
Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 <210> SEQ ID NO 5 <211> LENGTH:
124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 5 Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25
30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr
Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 6 <211>
LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody VkappaI V-region <400> SEQUENCE:
6 Ala Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr
Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr
Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 7 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 7
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Val Gly Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp
Asn Leu Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg
Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 8
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody VkappaI V-region
<400> SEQUENCE: 8 Asp Ile Gln Met Thr Gln Ser Pro Ser Phe Leu
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Arg Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Ser Ala Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Val Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85 90
95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210>
SEQ ID NO 9 <211> LENGTH: 124 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 9 Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Val Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 10 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaI V-region <400> SEQUENCE: 10 Asp
Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45 Tyr Asp Ala Ser Ala Leu Gln Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 11 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 11
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr
Ala 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Phe Arg Asp
Asn Pro Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg
Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
12 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VkappaI V-region
<400> SEQUENCE: 12 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Ser Ile Ser Arg Trp 20 25 30 Val Ala Trp Tyr Gln Gln
Arg Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 13 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 13 Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Pro Leu His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe
Ile Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 14 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vkappa V-region <400> SEQUENCE: 14 Asp Ile
Gln Leu Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Asp Ala Ser Ala Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln
Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 <210> SEQ ID NO 15 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 15
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser
Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
16 <211> LENGTH: 108 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VkappaIII V-region
<400> SEQUENCE: 16 Glu Ile Val Leu Thr Gln Phe Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Asn Val Gly Ser Ala 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Arg Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro 85
90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 17 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 17 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asp Gly Tyr Asn Lys Asp Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 18 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region <400> SEQUENCE: 18 Glu
Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 19 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 19
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30 Pro Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Phe Ile Ser Tyr Asp Gly Ser Glu Lys Tyr
Tyr Ala Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Glu Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
20 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VkappaIII V-region
<400> SEQUENCE: 20 Glu Ile Val Met Thr Gln Ser Pro Ala Thr
Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu Phe 35 40 45 Tyr Ala Ala Ser
Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 21 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 21 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Val Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn
Ile Trp Tyr Asp Gly Ser Ser Glu Ser Tyr Ile Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Arg Asn Thr Val Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 22 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region <400> SEQUENCE: 22 Glu
Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 23 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 23
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn
Tyr 20 25 30 Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Glu Lys Trp
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Gln Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
24 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody Vkappa V-region
<400> SEQUENCE: 24 Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Ser Val Thr Ile Thr Cys Arg
Ala Ser Glu Gly Val Asp Arg Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Asp Asp Val Ala Thr Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 25 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 25 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Pro Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Ser Tyr Asp Gly Ser Glu Lys Trp Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65
70 75 80 Leu Glu Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ser Trp Gly Gln Gly Thr Thr Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 26 <211> LENGTH: 124
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 26 Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25
30 Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Glu Lys Trp Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 27
<211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Vh V-region <400>
SEQUENCE: 27 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Ser Tyr 20 25 30 Pro Leu His Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe Ile Ser Tyr Asp Gly
Ser Glu Lys Tyr Tyr Ala Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala
Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105
110 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120
<210> SEQ ID NO 28 <211> LENGTH: 104 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vlambda
V-region <400> SEQUENCE: 28 Gln Ser Ala Leu Thr Gln Pro Ala
Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys
Thr Gly Thr Ser Ser Asp Tyr Val Ser Trp 20 25 30 Tyr Gln Gln His
Pro Gly Lys Ala Pro Lys Leu Ile Ile Tyr Asp Val 35 40 45 Thr Asn
Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser 50 55 60
Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp Glu 65
70 75 80 Ala Asp Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Tyr Thr
Phe Gly 85 90 95 Gly Gly Thr Lys Leu Thr Val Leu 100 <210>
SEQ ID NO 29 <211> LENGTH: 124 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 29 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Pro Leu His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Phe
Ile Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 30 <211> LENGTH: 106
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vlambda V-region <400> SEQUENCE: 30 Ser
Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10
15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala
20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val
Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg
Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile
Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln
His Phe Trp Ser Thr Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys
Leu Thr Val Leu 100 105 <210> SEQ ID NO 31 <400>
SEQUENCE: 31 000 <210> SEQ ID NO 32 <211> LENGTH: 106
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vlambda V-region <400> SEQUENCE: 32 Ser
Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10
15 Thr Val Thr Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Leu Tyr Ala
20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val
Leu Tyr 35 40 45 Ser Lys Asn Ser Arg Pro Ser Gly Ile Pro Asp Arg
Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile
Thr Gly Ala Arg Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln
His Phe Trp Ser Thr Pro Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys
Leu Thr Val Leu 100 105 <210> SEQ ID NO 33 <400>
SEQUENCE: 33 000 <210> SEQ ID NO 34 <211> LENGTH: 109
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vlambda V-region <400> SEQUENCE: 34 Gln
Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10
15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys Val Pro
Lys Leu 35 40 45 Ile Ile Tyr Glu Val Thr Lys Arg Pro Ser Gly Val
Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser
Leu Thr Val Ser Gly Leu 65 70 75 80 Arg Ala Glu Asp Glu Ala Asp Tyr
Tyr Cys Gln His Phe Trp Ser Thr 85 90 95 Pro Tyr Thr Phe Gly Gly
Gly Thr Lys Leu Thr Val Leu 100 105 <210> SEQ ID NO 35
<211> LENGTH: 124 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Vh V-region <400>
SEQUENCE: 35 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Asn Tyr 20 25 30 Pro Met His Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly
Ser Glu Lys Trp Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met
Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala
Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105
110 Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
<210> SEQ ID NO 36 <211> LENGTH: 107 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vkappa
V-region <400> SEQUENCE: 36 Asp Ile Gln Leu Thr Gln Ser Pro
Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Ser Val Thr Ile Thr
Cys Arg Ala Ser Glu Gly Val Asp Arg Trp 20 25 30 Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp
Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65
70 75 80 Asp Asp Val Ala Thr Tyr Tyr Cys Gln His Phe Trp Ser Thr
Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
105 <210> SEQ ID NO 37 <211> LENGTH: 107 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody VkappaI V-region <400> SEQUENCE: 37 Asp Ile Gln Met
Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg
Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Trp 20 25 30
Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Asn Leu Leu Ile 35
40 45 Tyr Asp Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe
Trp Gly Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 100 105 <210> SEQ ID NO 38 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody binding specificity determinant (BSD) in CDRH3
<400> SEQUENCE: 38 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr 1 5 10 <210> SEQ ID NO 39 <211> LENGTH: 5
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody binding specificity determinant (BSD) in CDRL3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (3)...(3) <223> OTHER INFORMATION: Xaa = Ser or Gly
<400> SEQUENCE: 39 Phe Trp Xaa Thr Pro 1 5 <210> SEQ ID
NO 40 <211> LENGTH: 5 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR3 <400>
SEQUENCE: 40 Phe Trp Gly Thr Pro 1 5 <210> SEQ ID NO 41
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody V-L region CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (2)...(2) <223> OTHER INFORMATION: Xaa = Gln or His
<400> SEQUENCE: 41 Gln Xaa Phe Trp Gly Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 42 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-H
region CDR3 <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (13)...(13) <223> OTHER INFORMATION:
Xaa = Met or Phe <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (15)...(15) <223> OTHER INFORMATION:
Xaa = Ile, Gln, Tyr or Ser <400> SEQUENCE: 42 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa Asp Xaa 1 5 10 15 <210>
SEQ ID NO 43 <211> LENGTH: 15 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-H
region CDR3 <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (15)...(15) <223> OTHER INFORMATION:
Xaa = Ile, Gln, Tyr or Ser <400> SEQUENCE: 43 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Xaa 1 5 10 15 <210>
SEQ ID NO 44 <211> LENGTH: 11 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody FR4
region <400> SEQUENCE: 44 Trp Gly Gln Gly Thr Ser Val Thr Val
Ser Ser 1 5 10 <210> SEQ ID NO 45 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-H region FR4 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (6)...(6) <223> OTHER
INFORMATION: Xaa = Thr or Met <400> SEQUENCE: 45 Trp Gly Gln
Gly Thr Xaa Val Thr Val Ser Ser 1 5 10 <210> SEQ ID NO 46
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody light chain CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (2)...(2) <223> OTHER INFORMATION: Xaa = His or Gln
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (5)...(5) <223> OTHER INFORMATION: Xaa = Gly or Ser
<400> SEQUENCE: 46 Gln Xaa Phe Trp Xaa Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 47 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-L
region FR4 <400> SEQUENCE: 47 Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 1 5 10 <210> SEQ ID NO 48 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-L region FR4 <400> SEQUENCE: 48 Phe Gly
Gly Gly Thr Lys Leu Thr Val Leu 1 5 10 <210> SEQ ID NO 49
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody heavy chain region CDR2
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (1)...(1) <223> OTHER INFORMATION: Xaa = Val, Phe
or Asn <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (3)...(3) <223> OTHER INFORMATION: Xaa
= Ser or Trp <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (7)...(7) <223> OTHER INFORMATION: Xaa
= Ser, Lys, Arg or Tyr <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (8)...(8) <223> OTHER
INFORMATION: Xaa = Asn, Ser, Asp or Glu <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (9)...(9)
<223> OTHER INFORMATION: Xaa = Lys, Ile or Glu <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(10)...(10) <223> OTHER INFORMATION: Xaa = Tyr, Ser, Asp or
Trp <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (12)...(12) <223> OTHER INFORMATION: Xaa = Ala or
Ile <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (13)...(13) <223> OTHER INFORMATION: Xaa = Asp or
Ser <400> SEQUENCE: 49 Xaa Ile Xaa Tyr Asx Gly Xaa Xaa Xaa
Xaa Tyr Xaa Xaa Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 50
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 50 Thr Ala Gly Met His 1 5 <210> SEQ ID NO 51
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 51 Ser Tyr Gly Ile His 1 5 <210> SEQ ID NO 52
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 52 Ser Tyr Gly Met His 1 5 <210> SEQ ID NO 53
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 53 Ser Tyr Pro Leu His 1 5 <210> SEQ ID NO 54
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 54 Asn Tyr Pro Met His 1 5 <210> SEQ ID NO 55
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 55 Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp
Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 56 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <400> SEQUENCE: 56 Phe Ile
Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser Ser Val Lys 1 5 10 15
Gly <210> SEQ ID NO 57 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody CDR2 <400> SEQUENCE: 57 Val Ile Ser Tyr Asp Gly Ser
Glu Lys Trp Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> SEQ
ID NO 58 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 58 Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala Asp
Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 59 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <400> SEQUENCE: 59 Val Ile
Trp Tyr Asp Gly Tyr Asn Lys Asp Tyr Ala Asp Ser Val Lys 1 5 10 15
Gly <210> SEQ ID NO 60 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody CDR2 <400> SEQUENCE: 60 Asn Ile Trp Tyr Asp Gly Ser
Ser Glu Ser Tyr Ile Asp Ser Val Lys 1 5 10 15 Gly <210> SEQ
ID NO 61 <211> LENGTH: 5 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VH region CDR1
<400> SEQUENCE: 61 Asp His Ala Ile Ser 1 5 <210> SEQ ID
NO 62 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VH region CDR2
<400> SEQUENCE: 62 Trp Ile Ser Pro Tyr Ser Gly Asn Pro Asn
Tyr Ala Gln Ser Leu Gln 1 5 10 15 Gly <210> SEQ ID NO 63
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody VH region CDR3
<400> SEQUENCE: 63 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Phe Asp Ile 1 5 10 15 <210> SEQ ID NO 64 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR1 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (5)...(5) <223> OTHER
INFORMATION: Xaa = Ser or Gly <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (6)...(6) <223> OTHER
INFORMATION: Xaa = Ile or Val <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (7)...(7) <223> OTHER
INFORMATION: Xaa = Ser or Asp <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (8)...(8) <223> OTHER
INFORMATION: Xaa = Ser, Arg or Thr <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (9)...(9) <223> OTHER
INFORMATION: Xaa = Trp or Tyr <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (10)...(10) <223>
OTHER INFORMATION: Xaa = Leu or Val <400> SEQUENCE: 64 Arg
Ala Ser Glx Xaa Xaa Xaa Xaa Xaa Xaa Ala 1 5 10 <210> SEQ ID
NO 65 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(1)...(1) <223> OTHER INFORMATION: Xaa = Asp or Ala
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (4)...(4) <223> OTHER INFORMATION: Xaa = Ser, Ala
or Thr <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (6)...(6) <223> OTHER INFORMATION: Xaa
= Glu, Gln or Lys <400> SEQUENCE: 65 Xaa Ala Ser Xaa Leu Xaa
Ser 1 5 <210> SEQ ID NO 66 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody CDR1 <400> SEQUENCE: 66 Arg Ala Ser Gln Gly Ile Ser
Thr Tyr Leu Ala 1 5 10 <210> SEQ ID NO 67 <211> LENGTH:
11 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <400> SEQUENCE: 67 Arg Ala Ser Gln
Gly Ile Ser Ser Trp Leu Ala 1 5 10 <210> SEQ ID NO 68
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 68 Arg Ala Ser Gln Ser Ile Ser Arg Trp Val Ala 1 5 10
<210> SEQ ID NO 69 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 69 Arg Ala Ser Glu Gly Val Asp Arg Trp Leu
Ala 1 5 10 <210> SEQ ID NO 70 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <400> SEQUENCE: 70 Ala Ala Ser Ser
Leu Gln Ser 1 5 <210> SEQ ID NO 71 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <400> SEQUENCE: 71 Asp Ala Ser Ser
Leu Lys Ser 1 5 <210> SEQ ID NO 72 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <400> SEQUENCE: 72 Asp Ala Ser Ala
Leu Gln Ser 1 5 <210> SEQ ID NO 73 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <400> SEQUENCE: 73 Asp Ala Ser Thr
Leu Gln Ser 1 5 <210> SEQ ID NO 74 <211> LENGTH: 12
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <400> SEQUENCE: 74 Arg Ala Ser Asn
Ser Val Gly Ala Tyr Asn Leu Ala 1 5 10 <210> SEQ ID NO 75
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 75 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10
<210> SEQ ID NO 76 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (1)...(1) <223> OTHER INFORMATION: Xaa = Ala or Gly
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (4)...(4) <223> OTHER INFORMATION: Xaa = Thr or Arg
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (7)...(7) <223> OTHER INFORMATION: Xaa = Thr or Pro
<400> SEQUENCE: 76 Xaa Ala Ser Xaa Arg Ala Xaa 1 5
<210> SEQ ID NO 77 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (8)...(8) <223> OTHER INFORMATION: Xaa = Tyr or Leu
<400> SEQUENCE: 77 Gln Gly Asp Ser Leu Arg Ser Xaa Tyr Ala
Ser 1 5 10 <210> SEQ ID NO 78 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (1)...(1) <223> OTHER
INFORMATION: Xaa = Gly or Ser <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (4)...(4) <223> OTHER
INFORMATION: Xaa = Asn or Ser <400> SEQUENCE: 78 Xaa Lys Asn
Xaa Arg Pro Ser 1 5 <210> SEQ ID NO 79 <211> LENGTH: 14
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <400> SEQUENCE: 79 Thr Gly Thr Ser
Ser Asp Val Gly Ala Tyr Asn Tyr Val Ser 1 5 10 <210> SEQ ID
NO 80 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 80 Thr Gly Thr Ser Ser Asp Tyr Val Ser 1 5 <210>
SEQ ID NO 81 <211> LENGTH: 7 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (1)...(1) <223> OTHER INFORMATION: Xaa = Glu or Asp
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (4)...(4) <223> OTHER INFORMATION: Xaa = Lys or Asn
<400> SEQUENCE: 81 Xaa Val Thr Xaa Arg Pro Ser 1 5
<210> SEQ ID NO 82 <211> LENGTH: 113 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
germ-line sequence VH1-18 <400> SEQUENCE: 82 Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35
40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys
Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser
Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr
Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Phe Asp Ile Trp Gly Gln
Gly Thr Met Val Thr Val Ser 100 105 110 Ser <210> SEQ ID NO
83 <211> LENGTH: 113 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody germ-line sequence
VH3-30.3 <400> SEQUENCE: 83 Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Met
Val Thr Val Ser 100 105 110 Ser <210> SEQ ID NO 84
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody germ-line JH6 <400>
SEQUENCE: 84 Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val
Ser Ser 1 5 10 15 <210> SEQ ID NO 85 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody germ-line sequence VkappaI L12 <400>
SEQUENCE: 85 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala
Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Ser Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Glu
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr
Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Asp Asp Phe
Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr 85 90 95 Thr
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID
NO 86 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VkappaIII L2
<400> SEQUENCE: 86 Glu Ile Val Met Thr Gln Ser Pro Ala Thr
Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser
Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 87 <211> LENGTH: 108 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
VkappaIII V-region <400> SEQUENCE: 87 Glu Ile Val Leu Thr Gln
Phe Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Asn Ser Val Gly Ala Tyr 20 25 30 Asn Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45
Ile Tyr Gly Ala Ser Arg Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50
55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu
Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp
Ser Thr Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile
Lys 100 105 <210> SEQ ID NO 88 <211> LENGTH: 108
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody germ-line sequence VL3 31 <400> SEQUENCE:
88 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr
Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val
Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro
Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser Gly Asn Thr Ala Ser Leu
Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr
Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85 90 95 Val Val Phe Gly
Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> SEQ ID NO 89
<211> LENGTH: 111 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody germ-line VL2 2c
<400> SEQUENCE: 89 Gln Ser Ala Leu Thr Gln Pro Pro Ser Ala
Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly
Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr
Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Glu
Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly
Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser 85
90 95 Asn Asn Phe Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110 <210> SEQ ID NO 90 <211> LENGTH: 109
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vlambda V-region <400> SEQUENCE: 90 Gln
Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10
15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys Val Pro
Lys Leu 35 40 45 Ile Ile Tyr Glu Val Thr Lys Arg Pro Ser Gly Val
Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser
Leu Thr Val Ser Gly Arg 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr
Tyr Cys Gln His Phe Trp Ser Thr 85 90 95 Pro Tyr Thr Phe Gly Gly
Gly Thr Lys Leu Thr Val Leu 100 105 <210> SEQ ID NO 91
<211> LENGTH: 114 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody heavy chain constant
region for Fd' <400> SEQUENCE: 91 Ala Ser Thr Lys Gly Pro Ser
Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly
Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55
60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val
Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr
Cys Pro Pro Cys 100 105 110 Pro Ala <210> SEQ ID NO 92
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody light chain (kappa)
constant region <400> SEQUENCE: 92 Arg Thr Val Ala Ala Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50
55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105 <210> SEQ ID NO 93 <211> LENGTH: 15 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody heavy chain CDR3 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (13)...(13) <223>
OTHER INFORMATION: Xaa = Met or Phe <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (15)...(15)
<223> OTHER INFORMATION: Xaa = Ile, Ser or Gln <400>
SEQUENCE: 93 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa
Asp Xaa 1 5 10 15 <210> SEQ ID NO 94 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody FR4 sequence <400> SEQUENCE: 94 Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 1 5 10 <210> SEQ ID NO 95
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody FR4 sequence <400>
SEQUENCE: 95 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5 10
<210> SEQ ID NO 96 <211> LENGTH: 26 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
combination of CDRH3 and FR4 sequences <400> SEQUENCE: 96 Asn
Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Phe Asp Ile Trp 1 5 10
15 Gly Gln Gly Thr Met Val Thr Val Ser Ser 20 25 <210> SEQ ID
NO 97 <211> LENGTH: 26 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody combination of
CDRH3 and FR4 sequences <400> SEQUENCE: 97 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Ile Trp 1 5 10 15 Gly Gln
Gly Thr Met Val Thr Val Ser Ser 20 25 <210> SEQ ID NO 98
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody combination of CDRH3 and
FR4 sequences <400> SEQUENCE: 98 Asn Arg Gly Asp Ile Tyr Tyr
Asp Phe Thr Tyr Ala Met Asp Ile Trp 1 5 10 15 Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 20 25 <210> SEQ ID NO 99 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR3 <400> SEQUENCE: 99 Asn Arg
Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Ile 1 5 10 15
<210> SEQ ID NO 100 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (13)...(13) <223> OTHER INFORMATION: Xaa = Met or
Phe <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (15)...(15) <223> OTHER INFORMATION: Xaa = Gln or
Ser <400> SEQUENCE: 100 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe
Thr Tyr Ala Xaa Asp Xaa 1 5 10 15 <210> SEQ ID NO 101
<211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody kappa chain CDRL3-FR4
combination <400> SEQUENCE: 101 Gln Gln Phe Trp Ser Thr Pro
Tyr Thr Phe Gly Gln Gly Thr Lys Leu 1 5 10 15 Glu Ile Lys
<210> SEQ ID NO 102 <211> LENGTH: 19 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody kappa
chain CDRL3-FR4 combination <400> SEQUENCE: 102 Gln His Phe
Trp Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu 1 5 10 15 Glu
Ile Lys <210> SEQ ID NO 103 <211> LENGTH: 19
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody lambda chain CDRL3-FR4 combination <400>
SEQUENCE: 103 Gln His Phe Trp Ser Thr Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Leu 1 5 10 15 Thr Val Leu <210> SEQ ID NO 104
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 104 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 1 5 10
<210> SEQ ID NO 105 <211> LENGTH: 8 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 105 Thr Gly Thr Ser Ser Asp Tyr Val 1 5
<210> SEQ ID NO 106 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 106 Gly Lys Asn Asn Arg Pro Ser 1 5
<210> SEQ ID NO 107 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 107 Glu Val Thr Lys Arg Pro Ser 1 5
<210> SEQ ID NO 108 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 108 Asp Val Thr Asn Arg Pro Ser 1 5
<210> SEQ ID NO 109 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 109 Gln Gln Phe Trp Ser Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 110 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 110 Gln His Phe Trp Gly Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 111 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 111 Gln His Phe Trp Ser Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 112 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody natural
wild-type human gamma-1 hinge for di-PEGylation <400>
SEQUENCE: 112 Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 <210>
SEQ ID NO 113 <211> LENGTH: 9 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Mutant
Hinge-1 for mono-PEGylation <400> SEQUENCE: 113 Thr His Thr
Ala Pro Pro Cys Pro Ala 1 5 <210> SEQ ID NO 114 <211>
LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Mutant Hinge-2 for mono-PEGylation
<400> SEQUENCE: 114 Thr His Thr Cys Pro Pro Ala Pro Ala 1 5
<210> SEQ ID NO 115 <211> LENGTH: 12 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vkappa
CDRL3 and FR4 <400> SEQUENCE: 115 Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 1 5 10 <210> SEQ ID NO 116 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody V-H region CDR3 <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (13)...(13)
<223> OTHER INFORMATION: Xaa = Met or Phe <400>
SEQUENCE: 116 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa
Asp Ile 1 5 10 15 <210> SEQ ID NO 117 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-L region CDR3 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (3)...(3) <223> OTHER
INFORMATION: Xaa = Ser or Gly <400> SEQUENCE: 117 Phe Trp Xaa
Thr Pro Tyr Thr 1 5 <210> SEQ ID NO 118 <211> LENGTH:
14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (9)...(9) <223> OTHER
INFORMATION: Xaa = Gly or Ala <400> SEQUENCE: 118 Thr Gly Thr
Ser Ser Asp Val Gly Xaa Tyr Asn Tyr Val Ser 1 5 10 <210> SEQ
ID NO 119 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(1)...(1) <223> OTHER INFORMATION: Xaa = Glu or Asp
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (3)...(3) <223> OTHER INFORMATION: Xaa = Ser or Thr
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (4)...(4) <223> OTHER INFORMATION: Xaa = Lys or Asn
<400> SEQUENCE: 119 Xaa Val Xaa Xaa Arg Pro Ser 1 5
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 119
<210> SEQ ID NO 1 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
(VH1) V-region <400> SEQUENCE: 1 Glu Ile Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp His 20 25 30 Ala Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly
Trp Ile Ser Pro Tyr Ser Gly Asn Pro Asn Tyr Ala Gln Ser Leu 50 55
60 Gln Gly Arg Val Ser Leu Thr Thr Asp Arg Ser Thr Arg Thr Ala Tyr
65 70 75 80 Met Glu Leu Arg Ser Leu Lys Ser Asp Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Phe Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 2 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaI V-region <400> SEQUENCE: 2 Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Trp 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln
Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 <210> SEQ ID NO 3 <211> LENGTH:
124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 3 Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Ala 20 25
30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr
Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 4 <211>
LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody VkappaI V-region <400> SEQUENCE:
4 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1
5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg
Trp 20 25 30 Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Asn
Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Lys Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu
Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr
Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 5 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 5
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser
Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp
Asn Pro Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg
Thr Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 6
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody VkappaI V-region
<400> SEQUENCE: 6 Ala Ile Gln Leu Thr Gln Ser Pro Ser Phe Leu
Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Ser Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu
Asp Val Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85 90
95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210>
SEQ ID NO 7 <211> LENGTH: 124 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 7 Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Val Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Leu Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 8 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaI V-region <400> SEQUENCE: 8 Asp Ile
Gln Met Thr Gln Ser Pro Ser Phe Leu Ser Ala Ser Val Gly 1 5 10
15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr Tyr 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Arg Gly Lys Ala Pro Lys Leu Leu
Ile 35 40 45 Ser Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Val Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln
Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 <210> SEQ ID NO 9 <211> LENGTH:
124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 9 Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Val Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Pro Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr
Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 10
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody VkappaI V-region
<400> SEQUENCE: 10 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 11 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 11 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Thr Ala 20 25 30 Gly Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Phe Arg Asp Asn Pro Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Ser Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 12 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaI V-region <400> SEQUENCE: 12 Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10
15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Arg Trp
20 25 30 Val Ala Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Asn Leu
Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Leu Lys Ser Gly Val Pro Ser
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 13 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 13
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30 Pro Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Phe Ile Ser Tyr Asp Gly Ser Glu Lys Tyr
Tyr Ala Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Glu Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
14 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody Vkappa V-region
<400> SEQUENCE: 14 Asp Ile Gln Leu Thr Gln Ser Pro Ser Phe
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Ala Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 15 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 15 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr 20 25 30 Gly Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 16 <211> LENGTH: 108
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region
<400> SEQUENCE: 16 Glu Ile Val Leu Thr Gln Phe Pro Gly Thr
Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Asn Val Gly Ser Ala 20 25 30 Tyr Leu Ala Trp Tyr Gln
Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala
Ser Arg Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Arg Leu Glu 65 70 75 80
Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro 85
90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 17 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 17 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val
Ile Trp Tyr Asp Gly Tyr Asn Lys Asp Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65
70 75 80 Leu Gln Ile Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 18 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region <400> SEQUENCE: 18 Glu
Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 19 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 19
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30 Pro Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ser Phe Ile Ser Tyr Asp Gly Ser Glu Lys Tyr
Tyr Ala Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Glu Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
20 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody VkappaIII V-region
<400> SEQUENCE: 20 Glu Ile Val Met Thr Gln Ser Pro Ala Thr
Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Gln Ala Pro Arg Leu Leu Phe 35 40 45 Tyr Ala Ala Ser
Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 21 <211> LENGTH: 124 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vh
V-region <400> SEQUENCE: 21 Glu Val Gln Leu Val Glu Ser Gly
Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys
Val Gly Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Ile His Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Asn
Ile Trp Tyr Asp Gly Ser Ser Glu Ser Tyr Ile Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Val Ser Arg Asp Asp Ser Arg Asn Thr Val Tyr 65
70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr
Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val Thr Val
Ser Ser 115 120 <210> SEQ ID NO 22 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region <400> SEQUENCE: 22 Glu
Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn
20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala
Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys
Gln Gln Phe Trp Ser Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 23 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 23
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn
Tyr 20 25 30 Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Glu Lys Trp
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Gln Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
24 <211> LENGTH: 107
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vkappa V-region <400> SEQUENCE: 24 Asp Ile
Gln Leu Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Ser Val Thr Ile Thr Cys Arg Ala Ser Glu Gly Val Asp Arg Trp 20
25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Arg Ala Pro Lys Leu Leu
Ile 35 40 45 Tyr Asp Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Ser Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Asp Asp Val Ala Thr Tyr Tyr Cys Gln
His Phe Trp Gly Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Leu Glu Ile Lys 100 105 <210> SEQ ID NO 25 <211>
LENGTH: 124 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vh V-region <400> SEQUENCE: 25
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5
10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn
Tyr 20 25 30 Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Glu Lys Trp
Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg
Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly
Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ser Trp Gly
Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> SEQ ID NO
26 <211> LENGTH: 124 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody Vh V-region
<400> SEQUENCE: 26 Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Asn Tyr 20 25 30 Pro Met His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser
Tyr Asp Gly Ser Glu Lys Trp Tyr Ala Asp Ser Val 50 55 60 Lys Gly
Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Glu Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85
90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met
Asp 100 105 110 Ile Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115
120 <210> SEQ ID NO 27 <211> LENGTH: 124 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody Vh V-region <400> SEQUENCE: 27 Glu Val Gln Leu Val
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Pro
Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45 Ser Phe Ile Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser Ser Val
50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu Asn Thr
Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala
Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr Tyr Asp
Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr Met Val
Thr Val Ser Ser 115 120 <210> SEQ ID NO 28 <211>
LENGTH: 104 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vlambda V-region <400> SEQUENCE:
28 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Tyr Val
Ser Trp 20 25 30 Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Ile
Ile Tyr Asp Val 35 40 45 Thr Asn Arg Pro Ser Gly Val Pro Asp Arg
Phe Ser Gly Ser Lys Ser 50 55 60 Gly Asn Thr Ala Ser Leu Thr Ile
Ser Gly Leu Gln Ala Glu Asp Glu 65 70 75 80 Ala Asp Tyr Tyr Cys Gln
His Phe Trp Ser Thr Pro Tyr Thr Phe Gly 85 90 95 Gly Gly Thr Lys
Leu Thr Val Leu 100 <210> SEQ ID NO 29 <211> LENGTH:
124 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 29 Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30 Pro Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ser Phe Ile Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Glu
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Ile Trp Gly Gln Gly Thr
Met Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 30
<211> LENGTH: 106 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Vlambda V-region
<400> SEQUENCE: 30 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val
Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly
Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn
Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser
Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Tyr Thr 85
90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210>
SEQ ID NO 31 <400> SEQUENCE: 31 000 <210> SEQ ID NO 32
<211> LENGTH: 106 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Vlambda V-region
<400> SEQUENCE: 32 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val
Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Thr Ile Thr Cys Gln Gly
Asp Ser Leu Arg Ser Leu Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Val Leu Val Leu Tyr 35 40 45 Ser Lys Asn Ser
Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60
Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Arg Ala Glu 65
70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro
Tyr Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105
<210> SEQ ID NO 33 <400> SEQUENCE: 33 000 <210>
SEQ ID NO 34 <211> LENGTH: 109 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vlambda
V-region <400> SEQUENCE: 34 Gln Ser Val Leu Thr Gln Pro Pro
Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys
Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 Asn Tyr Val Ser
Trp Tyr Gln Gln Tyr Pro Gly Lys Val Pro Lys Leu 35 40 45 Ile Ile
Tyr Glu Val Thr Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly Leu 65
70 75 80 Arg Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln His Phe Trp
Ser Thr 85 90 95 Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Thr Val
Leu 100 105 <210> SEQ ID NO 35 <211> LENGTH: 124
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Vh V-region <400> SEQUENCE: 35 Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25
30 Pro Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Glu Lys Trp Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Asn Ser Leu Arg Pro Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asn Arg Gly Asp Ile Tyr
Tyr Asp Phe Thr Tyr Ala Met Asp 100 105 110 Tyr Trp Gly Gln Gly Thr
Thr Val Thr Val Ser Ser 115 120 <210> SEQ ID NO 36
<211> LENGTH: 107 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Vkappa V-region
<400> SEQUENCE: 36 Asp Ile Gln Leu Thr Gln Ser Pro Ser Thr
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Ser Val Thr Ile Thr Cys Arg
Ala Ser Glu Gly Val Asp Arg Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Arg Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Ser Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Asp Asp Val Ala Thr Tyr Tyr Cys Gln His Phe Trp Ser Thr Pro Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 37 <211> LENGTH: 107 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody VkappaI
V-region <400> SEQUENCE: 37 Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr
Cys Arg Ala Ser Gln Ser Ile Ser Arg Trp 20 25 30 Val Ala Trp Tyr
Gln Gln Arg Pro Gly Lys Ala Pro Asn Leu Leu Ile 35 40 45 Tyr Asp
Ala Ser Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65
70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Trp Gly Thr
Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100
105 <210> SEQ ID NO 38 <211> LENGTH: 11 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody binding specificity determinant (BSD) in CDRH3 <400>
SEQUENCE: 38 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr 1 5 10
<210> SEQ ID NO 39 <211> LENGTH: 5 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody binding
specificity determinant (BSD) in CDRL3 <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (3)...(3)
<223> OTHER INFORMATION: Xaa = Ser or Gly <400>
SEQUENCE: 39 Phe Trp Xaa Thr Pro 1 5 <210> SEQ ID NO 40
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR3 <400>
SEQUENCE: 40 Phe Trp Gly Thr Pro 1 5 <210> SEQ ID NO 41
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody V-L region CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (2)...(2) <223> OTHER INFORMATION: Xaa = Gln or His
<400> SEQUENCE: 41 Gln Xaa Phe Trp Gly Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 42 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-H
region CDR3 <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (13)...(13) <223> OTHER INFORMATION:
Xaa = Met or Phe <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (15)...(15) <223> OTHER INFORMATION:
Xaa = Ile, Gln, Tyr or Ser <400> SEQUENCE: 42 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa Asp Xaa 1 5 10 15 <210>
SEQ ID NO 43 <211> LENGTH: 15 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-H
region CDR3 <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (15)...(15) <223> OTHER INFORMATION:
Xaa = Ile, Gln, Tyr or Ser <400> SEQUENCE: 43 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Xaa 1 5 10 15 <210>
SEQ ID NO 44 <211> LENGTH: 11 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody FR4
region <400> SEQUENCE: 44 Trp Gly Gln Gly Thr Ser Val Thr Val
Ser Ser 1 5 10 <210> SEQ ID NO 45 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-H region FR4 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (6)...(6) <223> OTHER
INFORMATION: Xaa = Thr or Met <400> SEQUENCE: 45 Trp Gly Gln
Gly Thr Xaa Val Thr Val Ser Ser 1 5 10 <210> SEQ ID NO 46
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody light chain CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (2)...(2) <223> OTHER INFORMATION: Xaa = His or Gln
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (5)...(5) <223> OTHER INFORMATION: Xaa = Gly or Ser
<400> SEQUENCE: 46 Gln Xaa Phe Trp Xaa Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 47 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody V-L
region FR4 <400> SEQUENCE: 47 Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 1 5 10 <210> SEQ ID NO 48 <211> LENGTH: 10
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-L region FR4 <400> SEQUENCE: 48 Phe Gly
Gly Gly Thr Lys Leu Thr Val Leu 1 5 10 <210> SEQ ID NO 49
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody heavy chain region CDR2
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (1)...(1) <223> OTHER INFORMATION: Xaa = Val, Phe
or Asn <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (3)...(3) <223> OTHER INFORMATION: Xaa
= Ser or Trp <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (7)...(7) <223> OTHER INFORMATION: Xaa
= Ser, Lys, Arg or Tyr <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (8)...(8) <223> OTHER
INFORMATION: Xaa = Asn, Ser, Asp or Glu <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (9)...(9)
<223> OTHER INFORMATION: Xaa = Lys, Ile or Glu <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(10)...(10) <223> OTHER INFORMATION: Xaa = Tyr, Ser, Asp or
Trp <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (12)...(12) <223> OTHER INFORMATION: Xaa = Ala or
Ile <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (13)...(13) <223> OTHER INFORMATION: Xaa = Asp or
Ser <400> SEQUENCE: 49 Xaa Ile Xaa Tyr Asx Gly Xaa Xaa Xaa
Xaa Tyr Xaa Xaa Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 50
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 50 Thr Ala Gly Met His 1 5 <210> SEQ ID NO 51
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 51 Ser Tyr Gly Ile His 1 5 <210> SEQ ID NO 52
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 52 Ser Tyr Gly Met His 1 5 <210> SEQ ID NO 53
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 53 Ser Tyr Pro Leu His 1 5 <210> SEQ ID NO 54
<211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 54 Asn Tyr Pro Met His 1 5 <210> SEQ ID NO 55
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 55 Val Ile Trp Tyr Asn Gly Lys Glu Ile Ser Tyr Ala Asp
Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 56 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <400> SEQUENCE: 56 Phe Ile
Ser Tyr Asp Gly Ser Glu Lys Tyr Tyr Ala Ser Ser Val Lys 1 5 10 15
Gly <210> SEQ ID NO 57 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody CDR2 <400> SEQUENCE: 57 Val Ile Ser Tyr Asp Gly Ser
Glu Lys Trp Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> SEQ
ID NO 58 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 58 Val Ile Trp Tyr Asp Gly Arg Asn Lys Tyr Tyr Ala Asp
Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 59
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 59 Val Ile Trp Tyr Asp Gly Tyr Asn Lys Asp Tyr Ala Asp
Ser Val Lys 1 5 10 15 Gly <210> SEQ ID NO 60 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <400> SEQUENCE: 60 Asn Ile
Trp Tyr Asp Gly Ser Ser Glu Ser Tyr Ile Asp Ser Val Lys 1 5 10 15
Gly <210> SEQ ID NO 61 <211> LENGTH: 5 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody VH region CDR1 <400> SEQUENCE: 61 Asp His Ala Ile
Ser 1 5 <210> SEQ ID NO 62 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody VH region CDR2 <400> SEQUENCE: 62 Trp Ile Ser Pro
Tyr Ser Gly Asn Pro Asn Tyr Ala Gln Ser Leu Gln 1 5 10 15 Gly
<210> SEQ ID NO 63 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody VH
region CDR3 <400> SEQUENCE: 63 Asn Arg Gly Asp Ile Tyr Tyr
Asp Phe Thr Tyr Ala Phe Asp Ile 1 5 10 15 <210> SEQ ID NO 64
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (5)...(5)
<223> OTHER INFORMATION: Xaa = Ser or Gly <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(6)...(6) <223> OTHER INFORMATION: Xaa = Ile or Val
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (7)...(7) <223> OTHER INFORMATION: Xaa = Ser or Asp
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (8)...(8) <223> OTHER INFORMATION: Xaa = Ser, Arg
or Thr <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (9)...(9) <223> OTHER INFORMATION: Xaa
= Trp or Tyr <220> FEATURE: <221> NAME/KEY: VARIANT
<222> LOCATION: (10)...(10) <223> OTHER INFORMATION:
Xaa = Leu or Val <400> SEQUENCE: 64 Arg Ala Ser Glx Xaa Xaa
Xaa Xaa Xaa Xaa Ala 1 5 10 <210> SEQ ID NO 65 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (1)...(1) <223> OTHER
INFORMATION: Xaa = Asp or Ala <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (4)...(4) <223> OTHER
INFORMATION: Xaa = Ser, Ala or Thr <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (6)...(6) <223> OTHER
INFORMATION: Xaa = Glu, Gln or Lys <400> SEQUENCE: 65 Xaa Ala
Ser Xaa Leu Xaa Ser 1 5 <210> SEQ ID NO 66 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR1 <400> SEQUENCE: 66 Arg Ala
Ser Gln Gly Ile Ser Thr Tyr Leu Ala 1 5 10 <210> SEQ ID NO 67
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 67 Arg Ala Ser Gln Gly Ile Ser Ser Trp Leu Ala 1 5 10
<210> SEQ ID NO 68 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 68 Arg Ala Ser Gln Ser Ile Ser Arg Trp Val
Ala 1 5 10 <210> SEQ ID NO 69 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <400> SEQUENCE: 69 Arg Ala Ser Glu
Gly Val Asp Arg Trp Leu Ala 1 5 10 <210> SEQ ID NO 70
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 70 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> SEQ ID NO
71 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 71 Asp Ala Ser Ser Leu Lys Ser 1 5 <210> SEQ ID NO
72 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 72 Asp Ala Ser Ala Leu Gln Ser 1 5 <210> SEQ ID NO
73 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <400>
SEQUENCE: 73 Asp Ala Ser Thr Leu Gln Ser 1 5 <210> SEQ ID NO
74 <211> LENGTH: 12 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 74 Arg Ala Ser Asn Ser Val Gly Ala Tyr Asn Leu Ala 1 5
10
<210> SEQ ID NO 75 <211> LENGTH: 11 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 75 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu
Ala 1 5 10 <210> SEQ ID NO 76 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR2 <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (1)...(1) <223> OTHER
INFORMATION: Xaa = Ala or Gly <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (4)...(4) <223> OTHER
INFORMATION: Xaa = Thr or Arg <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (7)...(7) <223> OTHER
INFORMATION: Xaa = Thr or Pro <400> SEQUENCE: 76 Xaa Ala Ser
Xaa Arg Ala Xaa 1 5 <210> SEQ ID NO 77 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (8)...(8) <223> OTHER
INFORMATION: Xaa = Tyr or Leu <400> SEQUENCE: 77 Gln Gly Asp
Ser Leu Arg Ser Xaa Tyr Ala Ser 1 5 10 <210> SEQ ID NO 78
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR2 <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (1)...(1)
<223> OTHER INFORMATION: Xaa = Gly or Ser <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(4)...(4) <223> OTHER INFORMATION: Xaa = Asn or Ser
<400> SEQUENCE: 78 Xaa Lys Asn Xaa Arg Pro Ser 1 5
<210> SEQ ID NO 79 <211> LENGTH: 14 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 79 Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
Asn Tyr Val Ser 1 5 10 <210> SEQ ID NO 80 <211> LENGTH:
9 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <400> SEQUENCE: 80 Thr Gly Thr Ser
Ser Asp Tyr Val Ser 1 5 <210> SEQ ID NO 81 <211>
LENGTH: 7 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR2 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (1)...(1) <223> OTHER
INFORMATION: Xaa = Glu or Asp <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (4)...(4) <223> OTHER
INFORMATION: Xaa = Lys or Asn <400> SEQUENCE: 81 Xaa Val Thr
Xaa Arg Pro Ser 1 5 <210> SEQ ID NO 82 <211> LENGTH:
113 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody germ-line sequence VH1-18 <400> SEQUENCE:
82 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
Ser Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly
Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr
Asn Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr
Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Arg Ser Leu
Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Phe
Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser 100 105 110 Ser
<210> SEQ ID NO 83 <211> LENGTH: 113 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
germ-line sequence VH3-30.3 <400> SEQUENCE: 83 Gln Val Gln
Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25
30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp
Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Phe Asp Ile Trp Gly
Gln Gly Thr Met Val Thr Val Ser 100 105 110 Ser <210> SEQ ID
NO 84 <211> LENGTH: 15 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody germ-line JH6
<400> SEQUENCE: 84 Gly Met Asp Val Trp Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 1 5 10 15 <210> SEQ ID NO 85 <211>
LENGTH: 107 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody germ-line sequence VkappaI L12
<400> SEQUENCE: 85 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr
Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Ser Ile Ser Ser Trp 20 25 30 Leu Ala Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser
Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly
Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Tyr 85
90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105
<210> SEQ ID NO 86 <211> LENGTH: 107 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
VkappaIII L2 <400> SEQUENCE: 86 Glu Ile Val Met Thr Gln Ser
Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35
40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr
Asn Asn Trp Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu
Ile Lys 100 105 <210> SEQ ID NO 87 <211> LENGTH: 108
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody VkappaIII V-region <400> SEQUENCE: 87 Glu
Ile Val Leu Thr Gln Phe Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10
15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Asn Ser Val Gly Ala Tyr
20 25 30 Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Arg Arg Ala Pro Gly Ile Pro
Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
Thr Ile Asn Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr
Cys Gln Gln Phe Trp Ser Thr Pro 85 90 95 Tyr Thr Phe Gly Gln Gly
Thr Lys Leu Glu Ile Lys 100 105 <210> SEQ ID NO 88
<211> LENGTH: 108 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody germ-line sequence VL3 31
<400> SEQUENCE: 88 Ser Ser Glu Leu Thr Gln Asp Pro Ala Val
Ser Val Ala Leu Gly Gln 1 5 10 15 Thr Val Arg Ile Thr Cys Gln Gly
Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Gly Lys Asn Asn
Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60 Ser Ser
Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ser Gly Asn His 85
90 95 Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105
<210> SEQ ID NO 89 <211> LENGTH: 111 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
germ-line VL2 2c <400> SEQUENCE: 89 Gln Ser Ala Leu Thr Gln
Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile
Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr
Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45
Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe 50
55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Val Ser Gly
Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr
Ala Gly Ser 85 90 95 Asn Asn Phe Val Val Phe Gly Gly Gly Thr Lys
Leu Thr Val Leu 100 105 110 <210> SEQ ID NO 90 <211>
LENGTH: 109 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody Vlambda V-region <400> SEQUENCE:
90 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln
1 5 10 15 Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly
Ala Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys
Val Pro Lys Leu 35 40 45 Ile Ile Tyr Glu Val Thr Lys Arg Pro Ser
Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr
Ala Ser Leu Thr Val Ser Gly Arg 65 70 75 80 Gln Ala Glu Asp Glu Ala
Asp Tyr Tyr Cys Gln His Phe Trp Ser Thr 85 90 95 Pro Tyr Thr Phe
Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> SEQ ID NO
91 <211> LENGTH: 114 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody heavy chain
constant region for Fd' <400> SEQUENCE: 91 Ala Ser Thr Lys
Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr
Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35
40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys
Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala <210> SEQ ID
NO 92 <211> LENGTH: 107 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody light chain (kappa)
constant region <400> SEQUENCE: 92 Arg Thr Val Ala Ala Pro
Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser
Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro
Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50
55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
Glu 65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
Leu Ser Ser 85 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105 <210> SEQ ID NO 93 <211> LENGTH: 15 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic anti-PcrV
antibody heavy chain CDR3 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (13)...(13) <223>
OTHER INFORMATION: Xaa = Met or Phe <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (15)...(15)
<223> OTHER INFORMATION: Xaa = Ile, Ser or Gln <400>
SEQUENCE: 93 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa
Asp Xaa 1 5 10 15 <210> SEQ ID NO 94 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody FR4 sequence <400> SEQUENCE: 94 Trp Gly
Gln Gly Thr Met Val Thr Val Ser Ser 1 5 10 <210> SEQ ID NO 95
<211> LENGTH: 11 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody FR4 sequence <400>
SEQUENCE: 95 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 1 5 10
<210> SEQ ID NO 96 <211> LENGTH: 26 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody
combination of CDRH3 and FR4 sequences <400> SEQUENCE: 96 Asn
Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Phe Asp Ile Trp 1 5 10
15 Gly Gln Gly Thr Met Val Thr Val Ser Ser 20 25 <210> SEQ ID
NO 97 <211> LENGTH: 26 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody combination of
CDRH3 and FR4 sequences <400> SEQUENCE: 97 Asn Arg Gly Asp
Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Ile Trp 1 5 10 15 Gly Gln
Gly Thr Met Val Thr Val Ser Ser 20 25 <210> SEQ ID NO 98
<211> LENGTH: 26 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody combination of CDRH3 and
FR4 sequences <400> SEQUENCE: 98 Asn Arg Gly Asp Ile Tyr Tyr
Asp Phe Thr Tyr Ala Met Asp Ile Trp 1 5 10 15 Gly Gln Gly Thr Thr
Val Thr Val Ser Ser 20 25 <210> SEQ ID NO 99 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody CDR3 <400> SEQUENCE: 99 Asn Arg
Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Met Asp Ile 1 5 10 15
<210> SEQ ID NO 100 <211> LENGTH: 15 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (13)...(13) <223> OTHER INFORMATION: Xaa = Met or
Phe <220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (15)...(15) <223> OTHER INFORMATION: Xaa = Gln or
Ser <400> SEQUENCE: 100 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe
Thr Tyr Ala Xaa Asp Xaa 1 5 10 15 <210> SEQ ID NO 101
<211> LENGTH: 19 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody kappa chain CDRL3-FR4
combination <400> SEQUENCE: 101 Gln Gln Phe Trp Ser Thr Pro
Tyr Thr Phe Gly Gln Gly Thr Lys Leu 1 5 10 15 Glu Ile Lys
<210> SEQ ID NO 102 <211> LENGTH: 19 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody kappa
chain CDRL3-FR4 combination <400> SEQUENCE: 102 Gln His Phe
Trp Gly Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Leu 1 5 10 15 Glu
Ile Lys <210> SEQ ID NO 103 <211> LENGTH: 19
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody lambda chain CDRL3-FR4 combination <400>
SEQUENCE: 103 Gln His Phe Trp Ser Thr Pro Tyr Thr Phe Gly Gly Gly
Thr Lys Leu 1 5 10 15 Thr Val Leu <210> SEQ ID NO 104
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody CDR1 <400>
SEQUENCE: 104 Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 1 5 10
<210> SEQ ID NO 105 <211> LENGTH: 8 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR1
<400> SEQUENCE: 105 Thr Gly Thr Ser Ser Asp Tyr Val 1 5
<210> SEQ ID NO 106 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 106 Gly Lys Asn Asn Arg Pro Ser 1 5
<210> SEQ ID NO 107 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 107 Glu Val Thr Lys Arg Pro Ser 1 5
<210> SEQ ID NO 108 <211> LENGTH: 7 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR2
<400> SEQUENCE: 108 Asp Val Thr Asn Arg Pro Ser 1 5
<210> SEQ ID NO 109 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 109 Gln Gln Phe Trp Ser Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 110 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 110 Gln His Phe Trp Gly Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 111 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody CDR3
<400> SEQUENCE: 111 Gln His Phe Trp Ser Thr Pro Tyr Thr 1 5
<210> SEQ ID NO 112 <211> LENGTH: 9 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody natural
wild-type human gamma-1 hinge for di-PEGylation <400>
SEQUENCE: 112
Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 <210> SEQ ID NO 113
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic anti-PcrV antibody Mutant Hinge-1 for
mono-PEGylation <400> SEQUENCE: 113 Thr His Thr Ala Pro Pro
Cys Pro Ala 1 5 <210> SEQ ID NO 114 <211> LENGTH: 9
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody Mutant Hinge-2 for mono-PEGylation <400>
SEQUENCE: 114 Thr His Thr Cys Pro Pro Ala Pro Ala 1 5 <210>
SEQ ID NO 115 <211> LENGTH: 12 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic anti-PcrV antibody Vkappa
CDRL3 and FR4 <400> SEQUENCE: 115 Tyr Thr Phe Gly Gln Gly Thr
Lys Leu Glu Ile Lys 1 5 10 <210> SEQ ID NO 116 <211>
LENGTH: 15 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic anti-PcrV antibody V-H region CDR3 <220> FEATURE:
<221> NAME/KEY: VARIANT <222> LOCATION: (13)...(13)
<223> OTHER INFORMATION: Xaa = Met or Phe <400>
SEQUENCE: 116 Asn Arg Gly Asp Ile Tyr Tyr Asp Phe Thr Tyr Ala Xaa
Asp Ile 1 5 10 15 <210> SEQ ID NO 117 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody V-L region CDR3 <220> FEATURE: <221>
NAME/KEY: VARIANT <222> LOCATION: (3)...(3) <223> OTHER
INFORMATION: Xaa = Ser or Gly <400> SEQUENCE: 117 Phe Trp Xaa
Thr Pro Tyr Thr 1 5 <210> SEQ ID NO 118 <211> LENGTH:
14 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
anti-PcrV antibody CDR1 <220> FEATURE: <221> NAME/KEY:
VARIANT <222> LOCATION: (9)...(9) <223> OTHER
INFORMATION: Xaa = Gly or Ala <400> SEQUENCE: 118 Thr Gly Thr
Ser Ser Asp Val Gly Xaa Tyr Asn Tyr Val Ser 1 5 10 <210> SEQ
ID NO 119 <211> LENGTH: 7 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic anti-PcrV antibody CDR2 <220>
FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION:
(1)...(1) <223> OTHER INFORMATION: Xaa = Glu or Asp
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (3)...(3) <223> OTHER INFORMATION: Xaa = Ser or Thr
<220> FEATURE: <221> NAME/KEY: VARIANT <222>
LOCATION: (4)...(4) <223> OTHER INFORMATION: Xaa = Lys or Asn
<400> SEQUENCE: 119 Xaa Val Xaa Xaa Arg Pro Ser 1 5
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.